FDA Clears Emerging 3D Ultrasound Technology

News
Article

The diagnostic tomographic 3D ultrasound imaging technology PIUR tUS inside will reportedly be available with select GE HealthCare Logiq systems.

Emphasizing proprietary sensor technology to provide tomographic 3D ultrasound imaging, the PIUR tUS inside modality has garnered 510(k) clearance from the Food and Drug Administration (FDA).

The PIUR tUS inside , which will be available with select GE HealthCare Logiq ultrasound systems, offers a combination of enhanced imaging, automated reporting and artificial intelligence (AI)-enabled segmentation, according to PIUR Imaging, the developer of PIUR tUS inside.

FDA Clears Emerging 3D Ultrasound Technology

Key attributes of the recently FDA-cleared PIUR tUS inside ultrasound modality include automated volume and nodule assessments, 3D image reconstruction and automated thyroid reporting. The PIUR tUS inside modality will be available with select GE HealthCare Logiq ultrasound systems, according to PIUR Imaging, the developer of PIUR tUS inside. (Image courtesy of PIUR Imaging.)

The company noted that key attributes of PIUR tUS inside include:

• automated 3D reconstruction of sagittal, transverse and coronal views from one sweep;

• automated volume and nodule assessment;

• AI-powered 3D segmentation with nodule and lobe measurements; and

• a combination of automated thyroid reporting and PACS integration for streamlined documentation.

“With the combination of this integrated solution and our previously FDA cleared Infinity system, PIUR IMAGING will continue to strengthen the role of enhanced 3D ultrasound imaging to improve patient outcomes in the U.S.,” said Tullio Giannitti, the general manager of PIUR Imaging.

Recent Videos
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.